<DOC>
	<DOCNO>NCT01449630</DOCNO>
	<brief_summary>This phase I study LY3031207 healthy subject . The purpose study look safety , well study drug tolerate , much study drug get blood stream long take body get rid give human . Information side effect may occur also collect . Subjects participate study approximately 3 month . This study research purpose intend treat medical condition .</brief_summary>
	<brief_title>A Study LY3031207 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Male subject agree use reliable method birth control study 3 month follow last dose investigational product Women childbearing potential due surgical sterilization ( least 6 week surgical bilateral oophorectomy without hysterectomy least 6 week tubal ligation ) confirm medical history menopause Menopausal woman include woman either spontaneous amenorrhea least 12 month , induce medical condition anorexia nervosa take medication amenorrhea induce amenorrhea ( eg. , oral contraceptive , hormone , gonadotropinreleasing hormone , antiestrogens , selective estrogen receptor modulators , chemotherapy ) spontaneous amenorrhea 6 12 month folliclestimulating hormone level great 40 mIU/mL Overtly healthy base history physical examination determine investigator Between body mass index ( BMI ) 18.5 32.0 kg/m^2 , inclusive Normotensive define supine systolic blood pressure ( BP ) &lt; 140 mmHg , diastolic BP &lt; 90 mmHg , without use antihypertensive , result judge clinically significant Investigator . Blood pressure may retested 2 additional time , well rested condition Clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Ex vivo whole blood prostaglandin E ( PGE ) synthesis lipopolysaccharide ( LPS ) stimulation le 5 ng/mL Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product unapproved use drug short halflife , within 5 halflife investigational product halflife longer 5 day , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY3031207 component formulation , celecoxib sulfonamide . Subjects know aspirin allergy allergic reaction nonsteroidal antiinflammatory drug ( NSAIDs ) also exclude Are person previously complete withdrawn study study investigate LY3031207 previously receive investigational product Have abnormality 12lead Electrocardiogram ( ECG ) , include QTc interval Bazett 's correction &gt; 450 msec men &gt; 470 msec woman abnormality , opinion investigator , increase risk associate participate study . Electrocardiogram may repeat 5 minute rest quietly , subject 's heart rate &gt; 75 beat per minute History , within last 2 year , presence active cardiovascular disease , include acute myocardial infarction , unstable angina , congestive heart failure , stroke , transient ischemic attack Presence clinically significant active bleed history bleed diathesis time screen Presence active peptic ulcer disease , Gastrointestinal ( GI ) bleeding , chronic gastritis , inflammatory bowel disease , chronic diarrhea , positive H. pylorus serology Evidence hepatitis C and/or positive hepatitis C antibody Evidence hepatitis B and/or positive hepatitis B surface antigen Evidence chronic liver disease , include chronic alcoholic disease ; nonalcoholic steatohepatitis ; recent ( within 3 month screen ) history acute viral hepatitis ; subject know Gilbert Syndrome History active neuropsychiatric disease Evidence human immunodeficiency virus ( HIV ) infection and/or positive HIV antibody Have significant history current cardiovascular , respiratory ( especially asthma chronic obstructive pulmonary disease ) , hepatic , renal , GI , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . History prior surgery ( least 3 month prior dose ) , splenectomy , cholecystectomy , appendectomy exclusionary Regularly use know drug abuse and/or show positive finding urinary drug screening Are woman positive pregnancy test woman lactate Intended use overthecounter medication prescription medication within 14 day prior dose , include limited antihypertensive , diuretic , antiplatelet anticoagulant drug , antidepressant Any use NSAIDs , celecoxib , aspirin acetaminophen ( dose &gt; 1 gm per day ) within 14 day screen Any use herbal dietary supplement , grapefruit and/or grapefruit juice , Seville oranges , starfruit , pomegranate within 14 day prior dose study drug Have donate blood 500 mL within last month Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) unwilling stop alcohol consumption duration study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Subjects smoke 10 cigarette per day unwilling follow Clinical Research Unit ( CRU ) smoking rule Subjects major surgery within 30 day prior screen subject plan surgery occur study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>